Surgical menopause: what removing the ovaries changes

What the word covers exactly

One confusion keeps coming back, and it deserves to be cleared up right away.

Hysterectomy removes the uterus. Periods stop, pregnancy is no longer possible, but if the ovaries are left in place they go on producing hormones. This is not menopause. It will come later, sometimes a little earlier than expected, without bleeding being available as a landmark.

Bilateral oophorectomy removes both ovaries. Here menopause is immediate: estrogen production collapses within a few hours. This is what is called surgical menopause.

The difference is not academic. It determines what your body will go through in the days after the operation, and what will have to be monitored for decades.

Why it is rougher than a natural menopause

Natural menopause settles in over several years. Hormone levels fluctuate, fall, rise again, fall again. It is unpleasant, but the body adjusts along the way.

After an oophorectomy there is no transition. Hot flashes can start in the very first days, often more intense than what women in natural menopause describe. Sleep, dryness, mood, libido: everything arrives at once, and sometimes while you are still recovering from an operation.

This has to be said clearly, because many women learn it after the fact: this abruptness is expected, it is not a sign that something went wrong.

What research documents over the long term

This is where precision is needed, because the subject has produced results that do not all point the same way, and presenting only half the literature would be dishonest.

A cohort study reported increased cardiovascular mortality after early bilateral oophorectomy¹. A review examined more broadly the effect of bilateral oophorectomy on women's long-term health².

Conversely, the analysis of the California Teachers Study concludes that bilateral oophorectomy is not associated with increased mortality⁶. This disagreement is not trivial: it comes down to age at the time of the operation, the reason for the operation, and above all whether or not hormone therapy was taken afterwards.

On the cognitive side, several pieces of work have explored the link between oophorectomy, estrogen and brain aging, including the hypothesis of a window of opportunity for treatment⁵ and an update devoted to oophorectomy and dementia⁷. Here again, these are associations in populations, not individual certainties.

What there is consensus on, however: a menopause occurring early, whatever its cause, exposes you to long-term consequences for bone, heart and cognition³.

What the French guideline draws from it

A divided literature does not prevent a clear recommendation. The clinical practice guidelines of the CNGOF devoted to hysterectomy for benign disease settle the matter this way: it is recommended to keep the ovaries in non-menopausal women, in the absence of ovarian disease or a history of breast or ovarian cancer, with grade B. The text notes that bilateral oophorectomy does reduce the risk of breast and ovarian cancer, but comes with an excess of overall mortality of cardiovascular origin.

In women who are already menopausal, the same text finds no justification for systematically removing the ovaries in the absence of a risk factor, and points out an excess risk of overall mortality when adnexectomy is combined with hysterectomy up to age 65. Nor does it recommend systematic removal of the tubes during a hysterectomy for benign disease, while indicating that this step can be discussed.

The particular situation of genetic risk

The reasoning is reversed in the presence of a BRCA1 or BRCA2 mutation. The guidelines of the French National Cancer Institute propose preventive bilateral adnexectomy from age 40 in case of a BRCA1 mutation, a step that can be deferred to around 45 in case of a BRCA2 mutation. They also specify that hormone therapy can be offered after this procedure in women free of cancer, following the prescribing rules of the general population, and that it remains contraindicated in case of a history of breast cancer.

The place of hormone therapy

This is the point where the situation of a woman operated on young differs radically from that of a woman going through menopause at 52.

When the ovaries are removed before the usual age of menopause, the body finds itself deprived of hormones for years it should have spent with them. The literature devoted to hormone therapy in young women with ovarian insufficiency of surgical origin addresses precisely this question⁴.

The logic that emerges is not that of a "comfort treatment" weighed on a benefit-risk balance as after 50: it is about replacing what is missing up to the age at which it would naturally have stopped. This is a conversation to have with the team following you, and it has an individual answer, particularly when the operation was prompted by a hormone-dependent cancer, a situation where everything is discussed differently.

GEMVi points the same way and gives a landmark for duration: treatment continues at least until the usual age of menopause, between 50 and 52, including when the ovaries were removed preventively in a context of genetic risk. Doses are often higher than those of a treatment started after 50. And if your uterus is in place, estrogen is never given alone: it must be combined with progesterone to protect the endometrium. If the uterus was removed at the same time as the ovaries, this combination is no longer necessary.

The contraindication to know is the same as in other situations: a history of breast cancer rules out hormone therapy. That is also the case when the operation itself was prompted by a hormone-dependent cancer.

Our article on hormone therapy sets the general framework; the one on early menopause covers non-surgical situations.

The questions to ask before the operation

When removal of the ovaries is being considered for a benign reason (endometriosis, cysts, uterine surgery), the question of keeping them genuinely arises. It arises differently depending on age, and differently again in the presence of a high genetic risk of cancer.

Five questions to ask, written down before the consultation:

• Is it necessary to remove both ovaries, or is one enough?
• What precise benefit is expected from removing them, and what risk is taken by keeping them?
• Given my age, will hormone therapy be offered afterwards, and until when?
• What symptoms can I expect in the weeks that follow?
• What follow-up is planned for bone and heart?

A decision made with full knowledge of the facts is lived through differently from a decision endured.

After the operation: what to keep an eye on

Bone. Density loss is faster when the hormonal drop is abrupt. A baseline bone density scan makes sense, and the usual levers (vitamin D, calcium intake, weight bearing) count for more. See our article on osteoporosis.

The heart. Blood pressure, lipids, tobacco, physical activity: these markers deserve to be monitored, independently of the scientific debate mentioned above.

Intimate life. Dryness and low desire are frequent and often unspoken. They have effective local solutions, independent of general treatment. See the genitourinary syndrome.

Mood. An abrupt hormonal drop has real psychological effects. It is not a weakness: it is an expected consequence, and it can be treated.

In summary

Surgical menopause is not a menopause brought forward by a few years: it is an event of a different nature, more abrupt, with documented long-term consequences and a literature that is not unanimous on their scale.

Two things follow. Before the operation, the question of keeping the ovaries deserves to be raised explicitly. Afterwards, monitoring bone and heart and the question of hormone therapy belong to the same conversation, and that conversation is yours to have.

⚠️ This article is provided for informational and educational purposes only. It does not replace medical advice, diagnosis or treatment. Always consult your doctor or a qualified health professional with any questions about your health.

How we work: our editorial method · Written and verified by Bouchra, editorial lead.